POLE and endometrial cancer: The amino-acids substituted in somatic POLE EDMs show a variable incidence rate (reviewed in [18,19]), with POLE-P286R being the most frequent variant in colorectal and endometrial cancer [16,21,26], reaching a frequency of ~7% in early-onset colorectal cancer [27].